News from August 2019
Researchers from University of Balikesir Report Details of New Studies and Findings in the Area of Antiemetic-Antivertigo Agents (The protective effect of metformin in scopolamine-induced learning and memory impairment in rats)
Disease Prevention Daily
2019 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Investigators discuss new findings in Drugs and Therapies - Antiemetic-Antivertigo Agents. According to news reporting originating from Balikesir, Turkey, by NewsRx correspondents, research stated, “Alzheimer’s disease (AD) is the most common neurodegenerative disease in the world. One of the most commonly prescribed oral antidiabetic drug, metformin, has been shown to have beneficial effects on restoring impaired cognitive function.”
Financial support for this research came from Balikesir Universitesi.
Our news editors obtained a quote from the research from the University of Balikesir, “In the present study, we investigated the effects of metformin on spatial memory in terms of alleviating scopolamine-induced learning and memory impairments in rats by using the Morris water maze (MWM) test and the modified elevated plus-maze (mEPM) test. Furthermore, we investigated the possible mechanisms of action of metformin in preventing cognitive dysfunction. Male Wistar rats received metformin (50, 100, or 200 mg/kg/day) via gavage feeding for three weeks. Scopolamine was administered intraperitoneally before the probe step of the MWM test or the acquisition session of the mEPM test. The learning and memory impairment induced by scopolamine was reversed by metformin. In addition, metformin improved the level of phosphorylated AMP-activated protein kinase and cAMP responsive element binding protein. However, metformin pretreatment had no impact on inhibiting the scopolamine-induced changes in acetylcholine levels. Furthermore, metformin exerted its antioxidant effect by significantly reversing scopolamine-induced changes in malondialdehyde, total antioxidant status, and superoxide dismutase levels in the hippocampus.”
According to the news editors, the research concluded: “Our results indicate that one of the most commonly used antidiabetic drug, metformin, has the potential to prevent the development of dementia and be a novel therapeutic drug for the amelioration of cognitive dysfunction in AD.”
For more information on this research see: The protective effect of metformin in scopolamine-induced learning and memory impairment in rats. Pharmacological Reports, 2019;71(5):818-825.
The news editors report that additional information may be obtained by contacting E. Aksoz, University of Balikesir, Faculty of Medicine, Dept. of Medical Pharmacology, Cagis Campus, Balikesir, Turkey. Additional authors for this research include S.S. Gocmez, T.D. Sahin, D. Aksit, H. Aksit and T. Utkan.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.pharep.2019.04.015. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.
- Published in